MacuMira Treatment for Dry AMD

Seamless implementation, full device support, and elevated care for your dry AMD patients.

Sign Up for More Information

Provide Your Patients Improved Vision with MacuMira

Delivering a diagnosis of dry AMD to a patient is hard. Having few options to preserve and protect their vision means letting them leave your clinic without a true resolution.

With MacuMira, you finally have a solution. You can provide real help instead of just hope.

MacuMira is a unique medical device that uses precisely delivered microcurrent to stimulate retinal pigment epithelium (RPE) cells, enhancing mitochondrial activity to support cellular energy production and preserve or improve visual function in people living with dry AMD.

All MacuMira providers receive comprehensive staff training and support from the start and throughout the lifetime of their device. Learn how MacuMira works, how you can equip your clinic with this singular eye disease treatment technology, and how you can gain a new tool to support your patients.

How MacuMira Works

Training Your Team

One of our certified MacuMira trainers will visit you for a half-day of hands-on training. By the end of the day, your team will be ready to provide MacuMira treatment to patients.

Seamless Implementation

MacuMira is designed to integrate smoothly into your existing patient flow. With straightforward protocols and intuitive operation, your team can get up to speed quickly, whether or not they have experience with similar technologies.

Microcurrent Stimulation

MacuMira uses Microcurrent Stimulation to support retinal health. It’s the first and only treatment of its kind for dry AMD, built on technology that has been safely used for decades.

Patented Waveform & Delivery

MacuMira’s patented Microcurrent Stimulation was developed to maximize therapeutic efficacy.  Our intuitive user interface is straightforward for a technician to operate.

Retinal Rejuvenation

MacuMira’s stimulation of RPE cells enhances mitochondrial ATP formation, leading to improved cellular function.

Maintaining Results

Patients often have noticeable improvement in visual function after the initial 10-day loading phase (4 x 32-minute sessions). These improvements can be maintained with treatment every 3 months.

How Can MacuMira Improve My Vision & Other Frequently Asked Questions

MacuMira delivers gentle microcurrent energy through your eyelids that stimulates the retina. This is designed to help support your visual function and slow the progression of dry AMD.

Treatments take place at your MacuMira provider’s eye care office, with each session lasting about 32 minutes.

During the treatment, you will be seated or reclined while a headset is placed over your eyes.
Contoured eye cups rest gently on your closed eyelids, delivering microcurrent stimulation to the retina. Many patients find it relaxing enough to fall asleep during treatment.

Some patients experience a mild tingling sensation or brief patterns of light during the session. These are known as phosphenes and are a normal response to the stimulation.

After the session, you can continue with your day as normal with no downtime or restrictions.

No, MacuMira treatment isn’t painful, and there are no needles or drugs involved. It’s completely noninvasive.

Some patients feel a slight tingling sensation during the session, but it’s generally very comfortable and well-tolerated.

Most patients report vision improvements within the first 10 days of treatment.

Results vary, but many dry AMD patients describe better contrast (ability to see detail in dim light), sharper reading vision, or less glare sensitivity after the initial 10-day phase of treatment.

Unfortunately, there is currently no cure for dry AMD. MacuMira is not a cure. However, it may help improve functional vision and slow progressive vision loss in people with dry AMD.

Many patients who receive MacuMira begin to notice improvements within the first 10 days during the initial loading phase of treatment.

To maintain those gains, follow-up treatments are typically recommended at least every 3 months. Your optometrist or ophthalmologist will determine the ideal schedule based on your condition and how your vision responds.

Yes, MacuMira can be used alongside your current vision aids and AREDS or AREDS2 supplements. It doesn’t interfere with any other aspects of your eye care.

Yes! MacuMira is a noninvasive treatment that has demonstrated a clinically proven strong safety profile. It has undergone rigorous safety review and licensing by Health Canada and meets the standards required of Class II medical devices.

The stimulation uses microcurrent levels that are incapable of causing muscle contraction and remain well below thresholds associated with discomfort or tissue damage.

No adverse events were reported in the prospective clinical study, and the treatment has now been used in clinical settings with excellent tolerability across thousands of treatment sessions.

Patients typically find the treatment comfortable and easy to complete. It doesn’t involve pills, lasers, injections, or any surgery.

There are currently no other authorized treatments for dry AMD, and nothing else has been shown to improve vision lost to dry AMD.

After diagnosing early stage dry AMD, eye care providers typically recommend lifestyle changes such as healthy eating, quitting smoking, and regular exercise to potentially slow the progression of dry AMD.

For intermediate dry AMD, eye care providers typically recommend dietary supplements, such as AREDS or AREDS2 vitamins. These may slow the progression of the disease, but do not improve vision.

Download the Clinical Trial

The MacuMira clinical trial, published in the International Journal of Retina and Vitreous, found the following:

100%

of patients in the treatment group showed improved vision

48%

of patients improved by at least 10 letters on the ETDRS acuity chart

8.2 ETDRS letters

Average improvement, along with a 25% average increase in ETDRS acuity

0

adverse effects of treatment

100%

of treated patients maintained their vision improvements for the duration of the trial

During the trial period, placebo group participants’ visual acuity decreased by 2 ETDRS letters read on average.

What’s the Best Thing You Can Do To Prevent Central Vision Loss In Your Patients?

What if vision loss didn’t have to be a guarantee for patients with dry AMD? At MacuMira, we see a future where that’s possible.

For more information on implementing MacuMira, clinical data, patient education strategies, or answers to any other questions, please register using the following form.

form here

Articles

Understanding how dry AMD affects you or your family member can make it a little easier to navigate. Learn more about this eye disease in our articles.

Your Guide to Dry Age-related Macular Degeneration: Key Treatments and Care Strategies

Blog

Dry age-related macular degeneration (AMD) is a progressive eye condition that affects the macula, leading to gradual central vision loss. As the most common form of AMD, it typically develops slowly. Early detection and management are crucial for maintaining eye health. Understanding  In dry AMD, the macula thins over time, often accompanied by the formation of […]

Read More… from Your Guide to Dry Age-related Macular Degeneration: Key Treatments and Care Strategies

July 23, 2025
MacuMira

Can Wet Macular Degeneration Turn Into Dry Macular Degeneration?

Blog

Age-related macular degeneration (AMD) is one of the leading causes of vision loss in older adults. It comes in two forms: dry (atrophic) and wet (neovascular). While dry AMD progresses gradually over time, wet AMD can cause sudden and severe vision loss. A common question among patients and caregivers is whether wet macular degeneration can turn […]

Read More… from Can Wet Macular Degeneration Turn Into Dry Macular Degeneration?

July 23, 2025
MacuMira

What is geographic atrophy (GA)?

Blog

How it’s related to dry AMD and who’s the most at risk For those with dry age-related macular degeneration (dry AMD), there’s always a risk that this condition could develop into geographic atrophy (GA), a condition where retinal pigment epithelial (RPE) cells start to die off. Research estimates that there are approximately 180,000 new cases of GA […]

Read More… from What is geographic atrophy (GA)?

July 23, 2025
MacuMira

Dry age-related macular degeneration (AMD) is a progressive eye condition that affects the macula, leading to gradual central vision loss. As the most common form of AMD, it typically develops slowly. Early detection and management are crucial for maintaining eye health. Understanding  In dry AMD, the macula thins over time, often accompanied by the formation of […]

Read More… from Your Guide to Dry Age-related Macular Degeneration: Key Treatments and Care Strategies

Age-related macular degeneration (AMD) is one of the leading causes of vision loss in older adults. It comes in two forms: dry (atrophic) and wet (neovascular). While dry AMD progresses gradually over time, wet AMD can cause sudden and severe vision loss. A common question among patients and caregivers is whether wet macular degeneration can turn […]

Read More… from Can Wet Macular Degeneration Turn Into Dry Macular Degeneration?

How it’s related to dry AMD and who’s the most at risk For those with dry age-related macular degeneration (dry AMD), there’s always a risk that this condition could develop into geographic atrophy (GA), a condition where retinal pigment epithelial (RPE) cells start to die off. Research estimates that there are approximately 180,000 new cases of GA […]

Read More… from What is geographic atrophy (GA)?

instagram facebook facebook2 pinterest twitter google-plus google linkedin2 yelp youtube phone location calendar share2 link star-full star star-half chevron-right chevron-left chevron-down chevron-up envelope fax